355 related articles for article (PubMed ID: 31585935)
1. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells.
Mota Reyes C; Teller S; Muckenhuber A; Konukiewitz B; Safak O; Weichert W; Friess H; Ceyhan GO; Demir IE
Clin Cancer Res; 2020 Jan; 26(1):220-231. PubMed ID: 31585935
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.
Shibuya KC; Goel VK; Xiong W; Sham JG; Pollack SM; Leahy AM; Whiting SH; Yeh MM; Yee C; Riddell SR; Pillarisetty VG
PLoS One; 2014; 9(5):e96565. PubMed ID: 24794217
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma.
Rupp L; Dietsche I; Kießler M; Sommer U; Muckenhuber A; Steiger K; van Eijck CWF; Richter L; Istvanffy R; Jäger C; Friess H; van Eijck CHJ; Demir IE; Reyes CM; Schmitz M
Front Immunol; 2024; 15():1378190. PubMed ID: 38629072
[TBL] [Abstract][Full Text] [Related]
4. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy.
Michelakos T; Cai L; Villani V; Sabbatino F; Kontos F; Fernández-Del Castillo C; Yamada T; Neyaz A; Taylor MS; Deshpande V; Kurokawa T; Ting DT; Qadan M; Weekes CD; Allen JN; Clark JW; Hong TS; Ryan DP; Wo JY; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
J Natl Cancer Inst; 2021 Feb; 113(2):182-191. PubMed ID: 32497200
[TBL] [Abstract][Full Text] [Related]
5. The role of 2-arachidonoylglycerol in the regulation of the tumor-immune microenvironment in murine models of pancreatic cancer.
Qiu C; Yang L; Wang B; Cui L; Li C; Zhuo Y; Zhang L; Zhang S; Zhang Q; Wang X
Biomed Pharmacother; 2019 Jul; 115():108952. PubMed ID: 31078044
[TBL] [Abstract][Full Text] [Related]
6. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
[TBL] [Abstract][Full Text] [Related]
7. Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer.
Das S; Shapiro B; Vucic EA; Vogt S; Bar-Sagi D
Cancer Res; 2020 Mar; 80(5):1088-1101. PubMed ID: 31915130
[TBL] [Abstract][Full Text] [Related]
8. Low intratumoral regulatory T cells and high peritumoral CD8(+) T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy.
Liu L; Zhao G; Wu W; Rong Y; Jin D; Wang D; Lou W; Qin X
Cancer Immunol Immunother; 2016 Jan; 65(1):73-82. PubMed ID: 26646849
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer.
Li C; Cui L; Yang L; Wang B; Zhuo Y; Zhang L; Wang X; Zhang Q; Zhang S
Pancreas; 2020 Jan; 49(1):120-127. PubMed ID: 31856087
[TBL] [Abstract][Full Text] [Related]
10. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
11. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
Christmas BJ; Rafie CI; Hopkins AC; Scott BA; Ma HS; Cruz KA; Woolman S; Armstrong TD; Connolly RM; Azad NA; Jaffee EM; Roussos Torres ET
Cancer Immunol Res; 2018 Dec; 6(12):1561-1577. PubMed ID: 30341213
[TBL] [Abstract][Full Text] [Related]
12. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
Front Immunol; 2021; 12():643529. PubMed ID: 33679807
[No Abstract] [Full Text] [Related]
13. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer.
Heiduk M; Plesca I; Glück J; Müller L; Digomann D; Reiche C; von Renesse J; Decker R; Kahlert C; Sommer U; Aust DE; Schmitz M; Weitz J; Seifert L; Seifert AM
JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509285
[TBL] [Abstract][Full Text] [Related]
14. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer.
Dias Costa A; Väyrynen SA; Chawla A; Zhang J; Väyrynen JP; Lau MC; Williams HL; Yuan C; Morales-Oyarvide V; Elganainy D; Singh H; Cleary JM; Perez K; Ng K; Freed-Pastor W; Mancias JD; Dougan SK; Wang J; Rubinson DA; Dunne RF; Kozak MM; Brais L; Reilly E; Clancy T; Linehan DC; Chang DT; Hezel AF; Koong AC; Aguirre AJ; Wolpin BM; Nowak JA
Clin Cancer Res; 2022 Dec; 28(23):5167-5179. PubMed ID: 36129461
[TBL] [Abstract][Full Text] [Related]
16. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
Farren MR; Sayegh L; Ware MB; Chen HR; Gong J; Liang Y; Krasinskas A; Maithel SK; Zaidi M; Sarmiento JM; Kooby D; Patel P; El-Rayes B; Shaib W; Lesinski GB
JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31830001
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
Wang K; Zhan Y; Huynh N; Dumesny C; Wang X; Asadi K; Herrmann D; Timpson P; Yang Y; Walsh K; Baldwin GS; Nikfarjam M; He H
Cancer Lett; 2020 Mar; 472():8-18. PubMed ID: 31857154
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma.
Siret C; Collignon A; Silvy F; Robert S; Cheyrol T; André P; Rigot V; Iovanna J; van de Pavert S; Lombardo D; Mas E; Martirosyan A
Front Immunol; 2019; 10():3070. PubMed ID: 32038621
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
Kuwabara S; Tsuchikawa T; Nakamura T; Hatanaka Y; Hatanaka KC; Sasaki K; Ono M; Umemoto K; Suzuki T; Sato O; Hane Y; Nakanishi Y; Asano T; Ebihara Y; Kurashima Y; Noji T; Murakami S; Okamura K; Shichinohe T; Hirano S
Cancer Sci; 2019 Jun; 110(6):1853-1862. PubMed ID: 30997706
[TBL] [Abstract][Full Text] [Related]
20. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
